Skip to content

Screening and Management of Hyperuricemia in Patients with Chronic Medical Diseases in Assiut University Hospital

Screening and Management of Hyperuricemia in Patients with Chronic Medical Diseases in Assiut University Hospital

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06586229
Enrollment
61
Registered
2024-09-19
Start date
2024-10-01
Completion date
2025-11-01
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Brief summary

In this study, we aimed to evaluate patients with chronic medical diseases in Assiut university hospitals for -Detection of asymptomatic hyperuricemia . * Early identification of associated comorbidities . * Management of indicated hyperurecimia .

Detailed description

Hyperuricemia is classically defined as a serum uric acid (SUA) of more than 7.0 mg/dL in men or more than 6.0 mg/dL in women . Asymptomatic hyperuricemia is a condition, where patients have elevated levels of SUA, yet do not exhibit symptoms or signs of monosodium urate crystal deposition, such as gout attacks, urolithiasis, or uric acid nephropathy . SUA can be elevated 10 to 15 years before clinical manifestations of gout . Up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia . Uric acid excretion mostly occurs via the kidneys, so decreased glomerular filtration rates in chronic kidney (CKD) patients contribute to the population increase in hyperuricemia. Conversely, studies suggest that hyperuricemia may contribute to CKD , raising the possibility that urate-lowering therapies (ULTs) could be useful in slowing CKD progression . There was no independent association between hyperuricemia and systemic arterial hypertension. Also, hyperuricemia has been reported as an independent risk factor for both coronary artery disease, congestive heart failure and diabetes mellitus. So efforts should be made to recognize individuals at risk of hyperuricemia by evaluating dietary habits, family history, and lifestyle factors, and regularly monitor SUA levels. As well as, management strategies, including lifestyle modifications, pharmacotherapy, and dietary interventions, to effectively control SUA and reduce the risk of associated complications.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients 18 years of age or older who were diagnosed with chronic medical diseases as diabetes mellitus , hypertension , obesity , metabolic syndrome , chronic kidney disease and cardiovascular disease (ischemic cardiomyopathy, heart failure ,coronary arteries disease) .

Exclusion criteria

* patients under the age of 18. * patients kown to have gouty arthritis * patients with acute kidney disease . * patients receiving thiazide diuretics. * patients with tumour lysis syndrome .

Design outcomes

Primary

MeasureTime frameDescription
screening for asymptomatic hyperuricaemiabaselineDetection of asymptomatic hyperuricemia patients with chronic medical diseases. Early identification of associated comorbidities . Management of indicated hyperurecimia .

Contacts

Primary ContactHuda A Khalafallah
hudaabdelkader.1998@gmail.com+2001156854695

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026